AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03755414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human Activity Profile
Description: * Screening, day 14, day 28, day 42, day 74, day 100, taper period, and follow-up (pilot study)~* Screening, day 14, day 28, day 42, day 60, day 74, day 100, day 180, taper period, and follow-up period (expansion study)
Study NCT00577018 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: o.d.
Study NCT03078010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin-tazobactam
Description: piperacillin-tazobactam (4.5 gm IV q 6 hrs)
Study NCT03078010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefepime
Description: (2 gm IV q 8 hrs)
Study NCT03379623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESCAPE-pain Programme
Description: The Enabling Self-management and Coping with Arthritic (knee) Pain using Exercise (ESCAPE-pain) is a programme of rehabilitation that integrates educational self-management and coping strategies for people with joint pain with an individualised exercise regimen for each participant. The implementation of the programme will be conducted by the researcher as a certified facilitator by using Clinician's training manual for the ESCAPE-pain programme.
Study NCT00805090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sporanox
Description: 200 mg
Study NCT00805090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium
Description: 37.5 mg
Study NCT01722162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT01722162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT01722162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Study NCT04144348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1653
Description: Sterile liquid for injection
Study NCT04144348 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile liquid for injection
Study NCT04481789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Suspension
Study NCT04481789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Tablets
Study NCT04481789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Tablets
Study NCT04481789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Tablets
Study NCT03783585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia
Description: The web-based CBT-I program is a 6-week interactive, online program that delivers typical CBT-I treatment techniques of stimulus control, sleep restriction, behavioral modifications, and cognitive restructuring.
Study NCT03783585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia + biweekly support
Description: Individuals randomized into the CBT-I + biweekly support will participate in CBT-I as described as well as a biweekly phone call or video call with research personnel for motivational interviewing.
Study NCT02524886 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GPi DBS with Medtronic electorde and Activa PC pulsegenerator
Description: The electric stimulation of 2 leads implanted in the Globus Pallidus internus
Study NCT02524886 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GPi DBS with Medtronic electorde and Activa PC pulsegenerator
Description: The electric stimulation of 2 leads implanted in the Globus Pallidus internus
Study NCT00487006 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serum Lab testing
Description: Serum Lab testing
Study NCT03297918 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle training
Description: The intervention is two-parted and includes weekly singing lessons in a choir, held by a professional instructor, with additional instructions for daily breathing exercise at home.
Study NCT00721708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chicken broth
Description: one time dose of chicken broth obtained from 150g of chicken breast
Study NCT04764877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Medicine
Description: Provided 15-20 minute long OMT session for patients in the OMT arm
Study NCT04031547 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Electrical Stimulation (tES)
Description: In tES, a mild electrical current is passed between two or more electrodes placed on the scalp.
Study NCT04031547 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Electrical Stimulation (tES)
Description: In tES, a mild electrical current is passed between two or more electrodes placed on the scalp.
Study NCT05014906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline 45 MG
Description: 45 mg oral minocyclineonce daily vs 45mg oral minocycline once daily in combination with use of 15% azelaic acid
Study NCT05014906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline 45 MG
Description: 45 mg oral minocyclineonce daily vs 45mg oral minocycline once daily in combination with use of 15% azelaic acid
Study NCT03762343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ultrasound guided Greater occipital nerve block
Description: ultrasound guided Greater occipital nerve block with 2 ml of bupivacaine 0.5% (up to a maximum of 2 mg/kg) subcutaneous under ultrasound guidance in the greater occipital nerve region bilaterally.
Study NCT03762343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control group C
Description: Patient in this group will receive the intraoperative standard of care(intraoperative intravenous fentanyl and paracetamol)
Study NCT01249469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin whitening cosmetic product
Description: Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit. The product is applied on one side of the hand
Study NCT01249469 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: skin whitening cosmetic product
Description: Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit. The product is applied on one side of the hand
Study NCT02312856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PulseRider
Description: Adjunctive device for endovascular embolization of intracranial aneurysms
Study NCT01892345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Induction Phase: 900 mg IV weekly for 4 weeks, followed by 1200 mg for the fifth dose; Maintenance Phase: 1200 mg IV every 2 weeks
Study NCT01892345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Induction Phase: matching placebo (900 mg) IV weekly for 4 weeks, followed by matching placebo (1200 mg) for the fifth dose; Maintenance Phase: matching placebo (1200 mg) IV every 2 weeks
Study NCT01488708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: 120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
Study NCT01488708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.
Study NCT03819582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeCee One intraocular lens
Description: Hydrophobic aspheric monofocal intraocular lens
Study NCT00615381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: insulin infusion (0-10 U/hr) vs. 0.3 U/kg/hr and boluses (0-8 U) adjusted every 15 minutes during the intraoperative period to maintain intraoperative euglycemia (blood glucose levels 80-120 mg/dL)
Study NCT00615381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: insulin infusion (0-10 U/hr) vs. 0.3 U/kg/hr and boluses (0-8 U) adjusted every 15 minutes during the intraoperative period to maintain intraoperative euglycemia (blood glucose levels 80-120 mg/dL)
Study NCT04590586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care (SoC) treatment for COVID-19 infection in line with institutional practice. The SoC may change as new information becomes available about treating COVID-19.
Study NCT04590586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Standard of care (SoC) treatment for COVID-19 infection in line with institutional practice. The SoC may change as new information becomes available about treating COVID-19.
Study NCT00425815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 24448
Description: Org 24448 is a moderate-potency selective AMPA positive modulator that enhances the glutamate system in the brain.
Study NCT00425815 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparison
Study NCT01363037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapivirine Vaginal Ring
Description: dosage form: dapivirine vaginal ring dosage:25 mg frequency:continuous use duration:28 days
Study NCT01363037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc Vaginal Ring
Description: dosage form: maraviroc vaginal ring dosage:100 mg frequency:continuous use duration:28 days
Study NCT01363037 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaginal Ring
Description: dosage form: placebo vaginal ring dosage:N/A frequency:continuous use duration:28 days
Study NCT01363037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine-Maraviroc Vaginal Ring
Description: dosage form: combination vaginal ring dosage:25 mg dapivirine + 100 mg maraviroc frequency:continuous use duration:28 days
Study NCT05150509 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oral Squamous Cell Carcinoma
Description: To identify the association of elevated level of specific amino acids in OSCC by Liquid Chromatography Mass Spectrometry
Study NCT00810368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carnosine
Description: 500mg Carnosine x2 daily
Study NCT00810368 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose placebo tablets x2 daily
Study NCT03915938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: S-ketamine will be administered in precalculated infusion rates to obtain a plasmatic level of 60 ng/ml
Study NCT04590586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast administered orally as a tablet.
Study NCT04590586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apremilast placebo
Description: Matching apremilast placebo administered orally as a tablet.
Study NCT04590586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Description: Lanadelumab administered as an intravenous (IV) infusion.
Study NCT04590586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lanadelumab placebo
Description: Matching lanadelumab placebo (normal saline) administered as an intravenous (IV) infusion.
Study NCT03915938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered in an identical way than ketamine.
Study NCT04590586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilucoplan
Description: Zilucoplan administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.
Study NCT04590586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zilucoplan placebo
Description: Matching zilucoplan placebo administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.
Study NCT03892382 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: High frequency rTMS to induce the long term potentiation in the left dorsolateral prefrontal cortex.
Study NCT03892382 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: High frequency rTMS to induce the long term potentiation in the left dorsolateral prefrontal cortex.
Study NCT03465618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging
Description: A low dose spiral CT is performed first per the standard procedure. These images will be used for both attenuation correction and registration of the serial image set. The initial PET brain scan will be acquired up to about 24 hours post injection. Based upon the discretion of the physician, non-surgical patients have the possibility of a second scan and third up to about 48 hours post injection. The times per bed position may be adjusted after the first patient is imaged, and his/her scans evaluated. Additional low dose CT scans will be performed at the image session for attenuation correction and image registration. PET study may be done on a PET-MR scanner for ease.
Study NCT03465618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and Urine samples
Description: Venous blood and urine samples will be obtained at approximately 0.5 hours post injection at the end of each scan
Study NCT01172223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myocet (Non-pegylated liposomal doxorubicin (NPLD))
Description: 60 mg/m\^2 i.v. day 1 q3 weeks
Study NCT01172223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2 i.v. day 1 q3 weeks
Study NCT01172223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib (GW572016, Tykerb)
Description: 750-1500 mg/d orally daily until the day of the definitive surgery
Study NCT02269228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin ER
Study NCT02269228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03830957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: 7.5 mg oral single dose if the heart rate would not reach to 60/minute then give another dose, 7.5 mg
Study NCT03830957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: 5 mg oral single dose if the heart rate would not reach to 60/minute then give another dose, 5 mg
Study NCT01567345 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable pump with continuous flow
Description: Insertion of an implantable pump filled up with the analgesic solution. Connection of the catheter to the intrathecal space. Continuous morphine's flow is scheduled.
Study NCT01567345 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable pump with programmable flow.
Description: Insertion of an implantable pump filled up with the analgesic solution. Connection of the catheter to the intrathecal space. Programmable morphine's flow is scheduled.
Study NCT02531776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subcutaneous insertions of needles
Description: Various types of needles with different designs and mechanical properties.~Five marketed needles are included: NovoFine 28G x 12 mm (Novo Nordisk A/S, Denmark), NovoFine 30G x 6 mm (Novo Nordisk A/S, Denmark), NovoFine 32G tip x 6 mm (Novo Nordisk A/S, Denmark), BD Ultra-Fine 32G x 4 mm Pentapoint (Beckton, Dickinson \& Company, USA), and Terumo Nanopass 34G x 5 mm (Terumo, Japan).~Ten needles have been exclusively manufactured for this clinical trial by Hart Needles, USA. These needles vary in diameter, number of needle tip grinding, and angles of grindings.~Three needles have been modified from the original (NovoFine 32G x 6 mm) with lack of lubrication or damaged needle tip for simulations of repeated use.~No drugs are injected. Only the needle insertion is evaluated.
Study NCT01033955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Loading dose: 40 mg (day 1) Maintenance dose: 20 mg (days 2-14)
Study NCT01033955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical appearing encapsulated placebo.
Study NCT05183308 — intervention group
Intervention type: DRUG
Intervention: Clodronic Acid
Description: Osteoporotic fracture treated with surgical and medical therapy
Study NCT03921840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ELDERFITNESS
Description: In person training: Participants will receive a 2-hour in person education session with the exercise trainer. Self-monitoring: Subjects will self-monitor subjects' level of physical activity (steps \& minutes of moderate activity) using the smartwatch. The Google calendar and Fitbit apps will send messages and alerts to the subject's smartwatch that encourage subjects to achieve subjects' daily goals. If a participant has low activity for 3 consecutive days, the research assistant will call the participant to either encourage the participant to adhere to the plan or provide a modified plan after consulting the exercise trainer.~Phone consultation: Subjects will have biweekly phone consultation with the research team members to receive guidance and adjustment on activity plans. Financial incentives: The intervention will include financial incentives. Specifically, when the daily activity goal is achieved for more than four days per week, a $5 reward will be given to subjects.
Study NCT03921840 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: General education on physical activity for older adults and continue daily activity and healthcare routine. Participants will also receive a Go4Life program book from the National Institute on Aging.
Study NCT02053142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir
Description: Single dose of acyclovir 200mg was given for pk study
Study NCT03273244 — intervention group
Intervention type: DEVICE
Intervention: NeuroSense monitoring and ANI monitoring
Description: From the start of palliative sedation, monitoring of EEG with NeuroSense device (WAVcns: Wavelet Anesthetic Value of the Central Nervous System) and ANI-monitoring (Analgesia Nociception Index) will be initiated.
Study NCT03532009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate
Description: Oral use for approximately 3 months
Study NCT03532009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral use for approximately 3 months
Study NCT03653195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: urine metabolomics
Description: We aim to determine of a specific urine metabolomic biomarkers can diagnose concussion.
Study NCT03653195 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: urine metabolomics
Description: We aim to determine of a specific urine metabolomic biomarkers can diagnose concussion.
Study NCT02053142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: Single dose of acyclovir 200mg was given for pk study
Study NCT04464226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide (Nubeqa, BAY1841788)
Description: Participants will continue receiving darolutamide treatment at the dose level and schedule of administration previously assigned in the feeder study.
Study NCT01300325 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 3% hypertonic saline solution
Description: Patients receive every 6 hours the nebulized 0.9% saline (Placebo comparator) (group I) or the 3% hypertonic saline solution group II) in addition to aerosolized epinephrine (1.5 mg) and to the conventional treatment (oxygen, fluids).
Study NCT01005303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 Tablet Daily
Study NCT01005303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Forceval plus 50 micrograms Vitamin D3
Description: Forceval: 1 Tablet Daily; Vitamin D3: 2 Tablets Daily
Study NCT02701335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neural mobilization
Description: The first 6 exercises consist of active range of motion movements of the hand designed to improve joint flexibility. The remaining 3 exercises are designed to strengthen grip and pinch by using a non-latex polymer ball: the Thera-Band Hand Exerciser (The Hygenic Corporation, Akron, OH) Subjects began with 10 repetitions the first 4 sessions, progressed to 12 repetitions the next 2 sessions, then 15 (2 sessions), and finally 20, if able, during the last sessions.
Study NCT02701335 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gloreha device
Description: Robotic assisted passive mobilization.
Study NCT02701335 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standardized exercise
Description: 9 exercises: active range of motion, strengthen grip and pinch
Study NCT02701335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standardized exercise
Description: 9 exercises: active range of motion, strengthen grip and pinch
Study NCT02053142 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo